Global Neurotrophic Keratitis Treatment Market Size, Status and Forecast 2019-2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Players Covered
- 1.4 Market Analysis by Type
- 1.4.1 Global Neurotrophic Keratitis Treatment Market Size Growth Rate by Type (2014-2025)
- 1.4.2 Preservative Free Artificial Tears
- 1.4.3 Topical Antibiotics
- 1.4.4 Tarsorraphy
- 1.4.5 Amniotic Membrane Transplantation
- 1.4.6 Bandage Contact Lenses
- 1.4.7 Recombinant Human Nerve Growth Factor
- 1.5 Market by Application
- 1.5.1 Global Neurotrophic Keratitis Treatment Market Share by Application (2019-2025)
- 1.5.2 Hospitals
- 1.5.3 Ambulatory Surgical Centers
- 1.5.4 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Global Growth Trends
- 2.1 Neurotrophic Keratitis Treatment Market Size
- 2.2 Neurotrophic Keratitis Treatment Growth Trends by Regions
- 2.2.1 Neurotrophic Keratitis Treatment Market Size by Regions (2019-2025)
- 2.2.2 Neurotrophic Keratitis Treatment Market Share by Regions (2014-2019)
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
- 2.3.3 Market Challenges
- 2.3.4 Porter’s Five Forces Analysis
3 Market Share by Key Players
- 3.1 Neurotrophic Keratitis Treatment Market Size by by Players
- 3.1.1 Global Neurotrophic Keratitis Treatment Revenue by by Players (2014-2019)
- 3.1.2 Global Neurotrophic Keratitis Treatment Revenue Market Share by by Players (2014-2019)
- 3.1.3 Global Neurotrophic Keratitis Treatment Market Concentration Ratio (CR5 and HHI)
- 3.2 Neurotrophic Keratitis Treatment Key Players Head office and Area Served
- 3.3 Key Players Neurotrophic Keratitis Treatment Product/Solution/Service
- 3.4 Date of Enter into Neurotrophic Keratitis Treatment Market
- 3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
- 4.1 Global Neurotrophic Keratitis Treatment Market Size by Type (2014-2019)
- 4.2 Global Neurotrophic Keratitis Treatment Market Size by Application (2014-2019)
5 North America
- 5.1 North America Neurotrophic Keratitis Treatment Market Size (2014-2019)
- 5.2 Neurotrophic Keratitis Treatment Key Players in North America
- 5.3 North America Neurotrophic Keratitis Treatment Market Size by Type
- 5.4 North America Neurotrophic Keratitis Treatment Market Size by Application
6 Europe
- 6.1 Europe Neurotrophic Keratitis Treatment Market Size (2014-2019)
- 6.2 Neurotrophic Keratitis Treatment Key Players in Europe
- 6.3 Europe Neurotrophic Keratitis Treatment Market Size by Type
- 6.4 Europe Neurotrophic Keratitis Treatment Market Size by Application
7 China
- 7.1 China Neurotrophic Keratitis Treatment Market Size (2014-2019)
- 7.2 Neurotrophic Keratitis Treatment Key Players in China
- 7.3 China Neurotrophic Keratitis Treatment Market Size by Type
- 7.4 China Neurotrophic Keratitis Treatment Market Size by Application
8 Japan
- 8.1 Japan Neurotrophic Keratitis Treatment Market Size (2014-2019)
- 8.2 Neurotrophic Keratitis Treatment Key Players in Japan
- 8.3 Japan Neurotrophic Keratitis Treatment Market Size by Type
- 8.4 Japan Neurotrophic Keratitis Treatment Market Size by Application
9 Southeast Asia
- 9.1 Southeast Asia Neurotrophic Keratitis Treatment Market Size (2014-2019)
- 9.2 Neurotrophic Keratitis Treatment Key Players in Southeast Asia
- 9.3 Southeast Asia Neurotrophic Keratitis Treatment Market Size by Type
- 9.4 Southeast Asia Neurotrophic Keratitis Treatment Market Size by Application
10 India
- 10.1 India Neurotrophic Keratitis Treatment Market Size (2014-2019)
- 10.2 Neurotrophic Keratitis Treatment Key Players in India
- 10.3 India Neurotrophic Keratitis Treatment Market Size by Type
- 10.4 India Neurotrophic Keratitis Treatment Market Size by Application
11 Central & South America
- 11.1 Central & South America Neurotrophic Keratitis Treatment Market Size (2014-2019)
- 11.2 Neurotrophic Keratitis Treatment Key Players in Central & South America
- 11.3 Central & South America Neurotrophic Keratitis Treatment Market Size by Type
- 11.4 Central & South America Neurotrophic Keratitis Treatment Market Size by Application
12 International Players Profiles
- 12.1 Allergan, Plc.
- 12.1.1 Allergan, Plc. Company Details
- 12.1.2 Company Description and Business Overview
- 12.1.3 Neurotrophic Keratitis Treatment Introduction
- 12.1.4 Allergan, Plc. Revenue in Neurotrophic Keratitis Treatment Business (2014-2019))
- 12.1.5 Allergan, Plc. Recent Development
- 12.2 Abbott Laboratories, Inc.
- 12.2.1 Abbott Laboratories, Inc. Company Details
- 12.2.2 Company Description and Business Overview
- 12.2.3 Neurotrophic Keratitis Treatment Introduction
- 12.2.4 Abbott Laboratories, Inc. Revenue in Neurotrophic Keratitis Treatment Business (2014-2019)
- 12.2.5 Abbott Laboratories, Inc. Recent Development
- 12.3 Bausch & Lomb Incorporated
- 12.3.1 Bausch & Lomb Incorporated Company Details
- 12.3.2 Company Description and Business Overview
- 12.3.3 Neurotrophic Keratitis Treatment Introduction
- 12.3.4 Bausch & Lomb Incorporated Revenue in Neurotrophic Keratitis Treatment Business (2014-2019)
- 12.3.5 Bausch & Lomb Incorporated Recent Development
- 12.4 Bayer AG
- 12.4.1 Bayer AG Company Details
- 12.4.2 Company Description and Business Overview
- 12.4.3 Neurotrophic Keratitis Treatment Introduction
- 12.4.4 Bayer AG Revenue in Neurotrophic Keratitis Treatment Business (2014-2019)
- 12.4.5 Bayer AG Recent Development
- 12.5 CooperVision
- 12.5.1 CooperVision Company Details
- 12.5.2 Company Description and Business Overview
- 12.5.3 Neurotrophic Keratitis Treatment Introduction
- 12.5.4 CooperVision Revenue in Neurotrophic Keratitis Treatment Business (2014-2019)
- 12.5.5 CooperVision Recent Development
- 12.6 Dompe farmaceutici S.p.A.
- 12.6.1 Dompe farmaceutici S.p.A. Company Details
- 12.6.2 Company Description and Business Overview
- 12.6.3 Neurotrophic Keratitis Treatment Introduction
- 12.6.4 Dompe farmaceutici S.p.A. Revenue in Neurotrophic Keratitis Treatment Business (2014-2019)
- 12.6.5 Dompe farmaceutici S.p.A. Recent Development
- 12.7 Johnson & Johnson
- 12.7.1 Johnson & Johnson Company Details
- 12.7.2 Company Description and Business Overview
- 12.7.3 Neurotrophic Keratitis Treatment Introduction
- 12.7.4 Johnson & Johnson Revenue in Neurotrophic Keratitis Treatment Business (2014-2019)
- 12.7.5 Johnson & Johnson Recent Development
- 12.8 Novartis AG
- 12.8.1 Novartis AG Company Details
- 12.8.2 Company Description and Business Overview
- 12.8.3 Neurotrophic Keratitis Treatment Introduction
- 12.8.4 Novartis AG Revenue in Neurotrophic Keratitis Treatment Business (2014-2019)
- 12.8.5 Novartis AG Recent Development
- 12.9 ReGenTree, LLC.
- 12.9.1 ReGenTree, LLC. Company Details
- 12.9.2 Company Description and Business Overview
- 12.9.3 Neurotrophic Keratitis Treatment Introduction
- 12.9.4 ReGenTree, LLC. Revenue in Neurotrophic Keratitis Treatment Business (2014-2019)
- 12.9.5 ReGenTree, LLC. Recent Development
- 12.10 Walgreens
- 12.10.1 Walgreens Company Details
- 12.10.2 Company Description and Business Overview
- 12.10.3 Neurotrophic Keratitis Treatment Introduction
- 12.10.4 Walgreens Revenue in Neurotrophic Keratitis Treatment Business (2014-2019)
- 12.10.5 Walgreens Recent Development
13 Market Forecast 2019-2025
- 13.1 Market Size Forecast by Product (2019-2025)
- 13.2 Market Size Forecast by Application (2019-2025)
- 13.3 Market Size Forecast by Regions
- 13.4 North America
- 13.5 Europe
- 13.6 China
- 13.7 Japan
- 13.8 Southeast Asia
- 13.9 India
- 13.10 Central & South America
14 Analyst's Viewpoints/Conclusions
15 Appendix
- 15.1 Research Methodology
- 15.1.1 Methodology/Research Approach
- 15.1.1.1 Research Programs/Design
- 15.1.1.2 Market Size Estimation
- 15.1.1.3 Market Breakdown and Data Triangulation
- 15.1.2 Data Source
- 15.1.2.1 Secondary Sources
- 15.1.2.2 Primary Sources
- 15.1.1 Methodology/Research Approach
- 15.2 Disclaimer
Neurotrophic keratitis is an orphan disease with a global prevalence rate of 5 per 10,000 people. It is manifested by the damage of trigeminal nucleus nerve innervations present in the eye corneal region which dampens the healing process of corneal injuries. The treatment approach is adopted as per the different stages of the disease.
In 2018, the global Neurotrophic Keratitis Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Neurotrophic Keratitis Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Neurotrophic Keratitis Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study
Allergan, Plc.
Abbott Laboratories, Inc.
Bausch & Lomb Incorporated
Bayer AG
CooperVision
Dompe farmaceutici S.p.A.
Johnson & Johnson
Novartis AG
ReGenTree, LLC.
Walgreens
Market segment by Type, the product can be split into
Preservative Free Artificial Tears
Topical Antibiotics
Tarsorraphy
Amniotic Membrane Transplantation
Bandage Contact Lenses
Recombinant Human Nerve Growth Factor
Market segment by Application, split into
Hospitals
Ambulatory Surgical Centers
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Neurotrophic Keratitis Treatment status, future forecast, growth opportunity, key market and key players.
To present the Neurotrophic Keratitis Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Neurotrophic Keratitis Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.